SHR-1501

Unknown / undisclosed

Phase 3underway

Evidence outlook · registrational

Non-Muscle Invasive Bladder Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-12.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Non-Muscle Invasive Bladder Cancer
NCT07726992 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-08-25 – 2030-08 · Papillary-Only Non-muscle-invasive Bladder Cancer
What this study did
Other / comorbidity
NCT07424287 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-07-13 – 2030-06 · NMIBC
What this study did
Phase 1/2 (3)
Non-Muscle Invasive Bladder Cancer
NCT06588179 · Fudan University
2024-10-01 – 2027-10-01 · NMIBC
What this study did
Other / comorbidity
NCT07073534 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2025-07-24 – 2027-12 · Patients With Advanced or Metastatic Malignant Tumors
What this study did
NCT05410730 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2022-11-23 – 2027-05 · High-risk NMIBC
What this study did
Phase 1 (2)
Other / comorbidity
NCT03995472 · Jiangsu HengRui Medicine Co., Ltd.
2020-02-14 – 2023-01-12 · Advanced Malignancies
What this study did
NCT04025957 · Jiangsu HengRui Medicine Co., Ltd.
2019-10-30 – 2022-07-31 · Advanced Malignancies
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Non-Muscle Invasive Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SHR-1501: this drugPhase 3UndisclosedIL-15not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
TAR-210Phase 3Intravesical Drug Delivery System (erdafitinib)—not yet gradedNo reviewed efficacy summary in this indication
TARA-002Phase 3Bacterial immunotherapyInnate and adaptive immune activation (inactivated Streptococcus pyogenes)not yet gradedNo reviewed efficacy summary in this indication
GIA632
Phase 2(overall)
Monoclonal antibodyIL-15
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08052667Phase 1Antibody–drug conjugateIntegrin beta-6 (ITGB6)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SHR-1501 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
Phase 1/2Non-Muscle Invasive Bladder CancerNot yet recruiting
Est. primary completion 2027-10-01 · NCT06588179 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Patients With Advanced or Metastatic Malignant TumorsRecruiting
Est. primary completion 2027-12 · NCT07073534 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 3Non-Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2029-12 · NCT07726992 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 3NMIBCRecruiting
Est. primary completion 2030-06 · NCT07424287 · CT.gov ↗
What to watch

See the full readout calendar ↗